Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 6/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 3/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13449494 | 1.00 | TDP1 (0.54) | TDP1MAPTALDH1A1HPGDPOLB | |
| SCHEMBL751103 | 1.00 | TDP1 (0.54) | TDP1MAPTALDH1A1HPGDPOLB | |
| SCHEMBL14435647 | 0.83 | TDP1 (0.59) | TDP1MAPTALDH1A1HPGDPOLB | |
| SCHEMBL6977513 | 0.77 | TDP1 (0.62) | TDP1MAPTALDH1A1HPGDPOLB | |
| SCHEMBL13221154 | 0.77 | TDP1 (0.62) | TDP1MAPTALDH1A1HPGDPOLB | |
| SCHEMBL678566 | 0.77 | TDP1 (0.62) | TDP1MAPTALDH1A1HPGDPOLB | |
| SCHEMBL24759814 | 0.75 | TDP1 (0.50) | TDP1MAPTALDH1A1HPGDPOLB | |
| SCHEMBL17361335 | 0.75 | TDP1 (0.50) | TDP1MAPTALDH1A1HPGDPOLB | |
| SCHEMBL17361336 | 0.75 | TDP1 (0.50) | TDP1MAPTALDH1A1HPGDPOLB | |
| SCHEMBL2034080 | 0.74 | TDP1 (0.48) | TDP1MAPTALDH1A1HPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398770-A1 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | ATROGI AB (SE) | 2024-12-05 | — | — | US | disclosed |
| US-12036210-B2 | Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia | ATROGI AB (SE) | 2024-07-16 | — | — | US | disclosed |
| US-11357757-B2 | Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia | ATROGI AB (SE) | 2022-06-14 | — | — | US | disclosed |
| US-20220133703-A1 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | ATROGI AB (SE) | 2022-05-05 | — | — | US | disclosed |
| EP-3971168-A1 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | Atrogi AB (SE) | 2022-03-23 | — | — | EP | disclosed |
| EP-3681872-B1 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | ATROGI AB (SE) | 2021-11-17 | — | — | EP | disclosed |
| US-20210030731-A1 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | ATROGI AB (SE) | 2021-02-04 | — | — | US | disclosed |
| EP-3681872-A1 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | Atrogi AB (SE) | 2020-07-22 | — | — | EP | disclosed |
| CN-111315726-A | Heteroaryl substituted β -hydroxyethylamines for the treatment of hyperglycemia | 阿托基公司 | 2020-06-19 | — | — | CN | disclosed |
| WO-2019053427-A1 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | ATROGI AB (SE) | 2019-03-21 | — | — | WO | disclosed |
| US-20050043323-A1 | Pyrimidylpyrrole derivatives active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-24 | — | — | US | disclosed |
| WO-2005014572-A1 | PYRIMIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-17 | — | — | WO | disclosed |
| CN-1571781-A | 4-imidazolin-2-one compounds | TANABE SEIYAKU CO (JP) | 2005-01-26 | — | — | CN | disclosed |
| US-20040204426-A1 | 4-Imidazolin-2-one compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-10-14 | — | — | US | disclosed |
| EP-1439174-A1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2004-07-21 | — | — | EP | disclosed |
| WO-2004058762-A1 | MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040116494-A1 | Use of IkappaB-kinase inhibitors in pain therapy | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-17 | — | — | US | disclosed |
| US-20040087568-A1 | Substituted anthranilic amide derivatives and methods of use | AMGEN INC. | 2004-05-06 | — | — | US | disclosed |
| WO-2004022057-A1 | USE OF IκB KINASE INHIBITORS FOR THE TREATMENT OF PAIN | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-03-18 | — | — | WO | disclosed |
| WO-2004022553-A1 | INDOLE OR BENZIMIDAZOLE DERIVATIVES FOR MODULATING IκB KINASE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133703-A1 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | SLC5A2, SLC5A1, GPR119 | TDP1 2770/4885MAPT 2765/4885ALDH1A1 986/4885 |
| US-11357757-B2 | Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia | SLC5A2, SLC5A1, GPR119 | TDP1 2770/4885MAPT 2765/4885ALDH1A1 986/4885 |
| US-20050043323-A1 | Pyrimidylpyrrole derivatives active as kinase inhibitors | TYMP, DTYMK, DCK | TDP1 1004/4885MAPT 3667/4885ALDH1A1 1562/4885 |
| US-20240398770-A1 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | SLC5A2, SLC5A1, GPR119 | TDP1 2783/4885MAPT 3147/4885ALDH1A1 827/4885 |
| US-20040204426-A1 | 4-Imidazolin-2-one compounds | NR3C1, NR3C2, SCN1B | TDP1 3398/4885MAPT 4542/4885ALDH1A1 755/4885 |
| US-20040087568-A1 | Substituted anthranilic amide derivatives and methods of use | AADAC, ASPH, EGLN3 | TDP1 3426/4885MAPT 4542/4885ALDH1A1 540/4885 |
| US-12036210-B2 | Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia | SLC5A2, SLC5A1, GPR119 | TDP1 2770/4885MAPT 2765/4885ALDH1A1 986/4885 |
| US-20210030731-A1 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | SLC5A2, SLC5A1, GPR119 | TDP1 2770/4885MAPT 2765/4885ALDH1A1 986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.